News

The Screening Antifungal Exposure in Intensive Care Units (SAFE-ICU) study, published in Intensive Care Medicine, provides important evidence on the adequacy of antifungal drug exposure in critically ill patients, an area where dosing guidance remains limited.

CRE RESPOND welcomes several international visitors each year to join us at UQCCR. Read about Richard's experience from his recent visit.

Brisbane Transplant Infectious Diseases Meeting brings cross-disciplinary insights to the forefront of patient care

CRE RESPOND’s Population Pharmacokinetics Workshop returns to Brisbane this July

Research Fellow

Research Fellow and Pharmacokinetic Analyst

CRE RESPOND welcomes several international visitors each year to join us at UQCCR. Read about Matthieu's experience from his recent visit.

CRE RESPOND welcomes several international visitors each year to join us at UQCCR. Read about Camilla's experience from her recent visit.

CRE RESPOND welcomes several international visitors each year to join us at UQCCR. Read about María's experience from her recent visit.

Resistance Optimised Antibiotic Dosing (The ROAD Study): Is dosing of meropenem and piperacillin-tazobactam optimised to prevent the emergence of antibiotic resistance safe and feasible in the ICU? A pilot study.

Antimicrobial stability is an important consideration for treatment planning and service delivery in outpatient parenteral antimicrobial therapy (OPAT) programmes. Regulation of stability assessment varies by region, and conflicting guidance and standards exist. This leads to disparity of equity in access and limits availability of certain antimicrobials for managing infections in the outpatient setting.